Mer­ck’s can­cer R&D jug­ger­naut ties up to lit­tle Drag­on­fly’s nat­ur­al born killer plat­form — with bil­lions on the line

A lit­tle more than a year af­ter Cel­gene bel­lied up to the part­ner­ship ta­ble with $33 mil­lion in cash to al­ly it­self with the up­start crew at Drag­on­fly, Mer­ck has now fol­lowed be­hind in search of what they’re hop­ing is a game-chang­ing ap­proach to treat­ing sol­id tu­mors.

“There’s no com­pa­ny that knows sol­id tu­mors more than Mer­ck,” says Drag­on­fly CEO Bill Haney, who re­cent­ly jumped in­to biotech with a pair of new com­pa­nies look­ing to make their mark in dif­fer­ent fields.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.